A phase 2a study assessing the efficacy and safety of STN1010905 ophthalmic suspension in subjects with MGD

A Phase 2a, Randomized, Evaluator-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010905 Ophthalmic Suspension Compared with Placebo in Subjects with MGD

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031240171

Enrollment

120

Registered

2024-06-18

Start date

2024-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MGD (Meibomian Gland Dysfunction)

Interventions

- Screening period : Artificial tear (BID, Both eyes) - Treatment period : High dose STN1010905 ophthalmic suspension, Low dose STN1010905 ophthalmic suspension or Placebo (BID, Both eyes)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Outpatient - Diagnosed as MGD based on the guideline - Having ocular symptoms

Exclusion criteria

Exclusion criteria: - Ocular disease which needs treatment expect MGD and dry eye - Requires contact lenses wear during the study - Any decision by the Investigator to terminate a subject in screening

Design outcomes

Primary

Measure	Time frame
Evaluation of meibomian gland by idra	—

Contacts

Public ContactYukie Migita

Santen pharmaceutical co.,ltd

clinical@santen.co.jp+81-6-4802-9341

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026